RxDoctor Payments Data

Marie Rivas

Family · Canton, GANPI 1730572512

Payments from drug & device makers

$12,927in general payments, 2019–2025

Across 339 payments — averaging $38.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$4K
  • Abbott$2K
  • Impulse Dynamics (USA) Inc.$1K
  • AstraZeneca$1K
  • Novartis$778
  • E.r. Squibb & Sons, L.L.C.$457
  • plus $4K from 23 others

What the payments were for

  • Travel & lodging$2,84522%
  • Food & beverage$10,08278%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,927 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$72,270
Medicare patients
232
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten49$391,881
EntrestoSacubitril/Valsartan115$109,089
JardianceEmpagliflozin100$105,375
FarxigaDapagliflozin Propanediol84$70,276
OzempicSemaglutide13$12,323
Spironolactone297$2,114
Metoprolol Succinate139$1,548
Torsemide66$1,287
Hydralazine Hcl52$882
Isosorbide Dinitrate15$854
Carvedilol89$787
Potassium Chloride24$585
Losartan Potassium78$534
Furosemide53$197
Digoxin12$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$457$391,88149 claims
NovartisEntresto$778$109,089115 claims
Boehringer IngelheimJardiance$147$105,375100 claims
AstraZenecaFarxiga$1,018$70,27684 claims
Novo NordiskOzempic$37$12,32313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →